

What is claimed is:

1. A pharmaceutical dosage form comprising an enteric-coated controlled release component,
wherein said enteric-coated controlled release component comprises a GABA_B agonist and a pharmaceutically acceptable excipient; and
wherein said dosage form exhibits an *in vitro* dissolution profile in simulated intestinal fluid medium comprising at least about 40% GABA_B agonist release after 1 hour, and at least about 70% GABA_B agonist release after 4 hours.
2. A pharmaceutical dosage form according to claim 1 wherein said GABA_B agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.
3. A pharmaceutical dosage form according to claim 2 wherein said baclofen is a racemic mixture.
4. A pharmaceutical dosage form according to claim 2 wherein said baclofen consists essentially of the L-baclofen enantiomer.
5. A pharmaceutical dosage form according to claim 2 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.
6. A pharmaceutical dosage form according to claim 2 wherein said baclofen is in the amount from about 2 mg to about 150 mg.
7. A pharmaceutical dosage form according to claim 2 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.
8. A pharmaceutical dosage form according to claim 1 wherein said dosage form is a tablet.
9. A pharmaceutical dosage form according to claim 1 wherein said dosage form is a capsule.
10. A pharmaceutical dosage form according to claim 9 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

11. A pharmaceutical dosage form comprising an enteric-coated controlled release component,
wherein said enteric-coated controlled release component comprises a GABA_B agonist and a pharmaceutically acceptable excipient; and
wherein said dosage form exhibits an *in vitro* dissolution profile in simulated gastric fluid/simulated intestinal fluid (2 hour switchover) medium comprising less than about 10% GABA_B agonist release after 2 hours, at least about 40% GABA_B agonist release after 3 hours, and at least about 70% GABA_B agonist release after 6 hours.
12. A pharmaceutical dosage form according to claim 11 wherein said GABA_B agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.
13. A pharmaceutical dosage form according to claim 12 wherein said baclofen is a racemic mixture.
14. A pharmaceutical dosage form according to claim 12 wherein said baclofen consists essentially of the L-baclofen enantiomer.
15. A pharmaceutical dosage form according to claim 12 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.
16. A pharmaceutical dosage form according to claim 12 wherein said baclofen is in the amount from about 2 mg to about 150 mg.
17. A pharmaceutical dosage form according to claim 12 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.
18. A pharmaceutical dosage form according to claim 11 wherein said dosage form is a tablet.
19. A pharmaceutical dosage form according to claim 11 wherein said dosage form is a capsule.
20. A pharmaceutical dosage form according to claim 19 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.
21. A pharmaceutical dosage form comprising an enteric-coated controlled release component,

wherein said enteric-coated controlled release component each comprises a GABA_B agonist and a pharmaceutically acceptable excipient; and

wherein said dosage form exhibits an *in vivo* plasma profile comprising mean maximum GABA_B agonist release from about 30 minutes to about 7 hours after administration to a fasting patient.

22. A pharmaceutical dosage form according to claim 21 wherein said *in vivo* plasma profile comprises mean maximum GABA_B agonist release from about 1 hour to about 5.5 hours after administration to a fasting patient.

23. A pharmaceutical dosage form according to claim 21 wherein said *in vivo* plasma profile comprises mean maximum GABA_B agonist release from about 90 minutes to about 5.5 hours after administration to a fasting patient.

24. A pharmaceutical dosage form according to claim 21 wherein said *in vivo* plasma profile comprises mean maximum GABA_B agonist release from about 2 hours to about 5.5 hours after administration to a fasting patient.

25. A pharmaceutical dosage form according to claim 21 wherein said GABA_B agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

26. A pharmaceutical dosage form according to claim 25 wherein said baclofen is a racemic mixture.

27. A pharmaceutical dosage form according to claim 25 wherein said baclofen consists essentially of the L-baclofen enantiomer.

28. A pharmaceutical dosage form according to claim 25 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

29. A pharmaceutical dosage form according to claim 25 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

30. A pharmaceutical dosage form according to claim 25 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

31. A pharmaceutical dosage form according to claim 21 wherein said dosage form is a tablet.

32. A pharmaceutical dosage form according to claim 21 wherein said dosage form is a capsule.

33. A pharmaceutical dosage form according to claim 32 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

34. A pharmaceutical dosage form comprising an enteric-coated controlled release component,

wherein said enteric-coated controlled release component comprises a GABA_B agonist and a pharmaceutically acceptable excipient; and

wherein said dosage form exhibits an *in vivo* plasma profile comprising at least two hours of sustained GABA_B agonist concentrations at greater than therapeutic levels, after about 2 hours following administration to a fasting patient.

35. A pharmaceutical dosage form according to claim 34 wherein said dosage form further comprises less than about 10% GABA_B agonist release in the stomach.

36. A pharmaceutical dosage form according to claim 34 wherein said dosage form further comprises at least about 25% GABA_B agonist release in the intestinal tract.

37. A pharmaceutical dosage form according to claim 34 wherein said dosage form further comprises substantially complete GABA_B agonist release after about 10 hours following administration to a fasting patient.

38. A pharmaceutical dosage form according to claim 34 wherein said GABA_B agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

39. A pharmaceutical dosage form according to claim 38 wherein said baclofen is a racemic mixture.

40. A pharmaceutical dosage form according to claim 38 wherein said baclofen consists essentially of the L-baclofen enantiomer.

41. A pharmaceutical dosage form according to claim 38 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

42. A pharmaceutical dosage form according to claim 38 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

43. A pharmaceutical dosage form according to claim 38 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

44. A pharmaceutical dosage form according to claim 34 wherein said dosage form is a tablet.

45. A pharmaceutical dosage form according to claim 34 wherein said dosage form is a capsule.

46. A pharmaceutical dosage form according to claim 45 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.